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in 2004–2005, 15% of Australians reported having arthritis.1 
Osteoarthritis (OA) is by far the most common form, and is a 
leading cause of pain and disability among people over 65 
years of age.2
 
Nonsteroidal anti-inflammatory drugs (NSAIDs), while not first line, 
have long been a mainstay of OA treatment but may be associated 
with adverse effects, particularly in the elderly. COX-2 inhibitors 
(C2I) were developed as it was considered theoretically plausible 
that they wouldn’t cause gastrointestinal side effects such as gastric 
erosion.3 This was borne out by multiple large randomised controlled 
trials (Table 1). 
This series of articles facilitated by the Australian Cochrane 
Musculoskeletal Group aims to place the findings of recent Cochrane 
musculoskeletal reviews in a context immediately relevant to general 
practitioners. This article looks at treatment options for osteoarthritis.
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Table 1. Key trials: ulcer complications with nonselective NSAIDs vs. selective C2Is
trial Drugs and doses total number  
of participants
Key results
SUCCESS8 Celecoxib 100 mg twice per day, or  
Celecoxib 200 mg twice per day, or  
Diclofenac 50 mg twice per day, or  
Naproxen 500 mg twice per day
13 274 •Oddsofulcercomplication>7timesgreaterinNSAIDthan
celecoxib group
•Nosignificantdifferenceifparticipantsalsoonaspirin
•Notpoweredtodetectcardiovasculardifferences
•Celecoxib100mgtwiceperdayand200mgtwiceperday
equally efficacious for OA 
VIGOR9 Rofecoxib (Vioxx) 50 mg/day, or 
Naproxen 500 mg twice per day
8076 •Relativeriskofacomplicatedgastrointestinaleventonrofecoxib
compared with naproxen is 0.4
•Patientshadrheumatoidarthritis
Table 2. Summary of Cochrane review on tramadol for osteoarthritis10
•Thereviewincluded11RCTs,inwhich1019adultswithOAofhipand/or
knee received tramadol or tramadol/paracetamol and 920 received placebo 
or active control. Average length of follow up was 35 days (range 7–91 days)
•Tramadolratedslightlybetterthanplaceboforpaincontrolasmeasured
by a pain scale, but the clinical significance of the measured difference is 
doubtful 
•Onetrialof20participantsfoundparacetamol1500mg/daywasmore
effective than 150 mg/day of tramadol for pain control and had fewer side 
effects
•OnetrialcomparedtramadolwithanNSAID(diclofenac).Thetwodrugshad
similar effects on function with roughly half of participants in both groups 
reporting at least moderate overall improvement. Over the 2 month follow 
up period there were significantly more minor adverse events with tramadol 
than with diclofenac
•Comparedwithplacebo,tramadolincreasedthelikelihoodofatleast
moderate overall improvement with a NNTB of 6. However, people taking 
tramadol were more than twice as likely as those taking placebo to have a 
minor adverse event such as vomiting, headache or constipation – NNTH is 5 
NNTB = number needed to treat to benefit, NNTH = number needed to treat to harm
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placebo.6 Nonetheless, concern about the safety of NSAIDs as 
a whole persists, as diclofenac and others have been linked to 
adverse cardiovascular outcomes.7
 In this setting, the need for a safe, effective oral treatment 
for OA is pressing. Two possibilities – apart from paracetamol – 
include tramadol and glucosamine. The results are summarised in 
Table 2 and 3 and how these results might 
affect practice are shown in Table 4.
conclusion 
Glucosamine seems safe but  i t  is 
controversial whether it benefits pain or 
function. Emerging evidence suggests 
that it may help both alone and when 
combined with chondroitin in the group that 
has moderate to severe knee symptoms. 
The optimum dose seems to be 1500 mg 
once daily. Tramadol has marginal effects 
on OA pain and can bring about functional 
improvement. It has a higher rate of 
unpleasant side effects in the short term 
than diclofenac and placebo, but its long 
term effects (vs. those associated with 
NSAIDs) are unknown. 
Conflict of interest: none declared.
 In 2004, the C2I rofecoxib (Vioxx) was withdrawn from the 
market after it was found that the relative risk of a cardiovascular 
event compared with placebo after 18 months of therapy was 
1.8.4 Concern was raised about celecoxib’s safety, particularly 
in higher doses.5 A recent meta-analysis found the risk of a 
cardiovascular event to be the same with celecoxib as with 
Table 4. Putting evidence into practice
case study
Mrs Jones, 55 years of age, is a teacher with moderate left knee OA and borderline hypertension. She is 
increasingly uncomfortable about taking Celebrex. She already takes paracetamol regularly and didn’t tolerate 
diclofenac or ibuprofen. What can you advise her?
You can advise her that while celecoxib in high dose (800 mg/day and 200 mg twice daily, but not 400 mg once daily) 
does appear to increase the risk of cardiovascular events, 200 mg once daily has not been linked to heart disease. 
Her brother has been prescribed tramadol for knee pain. Would it be worth trying that?
You can tell Mrs Jones that tramadol was only very slightly better than a placebo for OA pain, and about the same 
as diclofenac for its ability to bring about overall improvement. However, in the short term tramadol was much 
more likely to cause side effects such as vomiting, headache, constipation and dizziness than diclofenac. One in 6 
people who take tramadol will get unpleasant minor side effects, and one in 5 will get a sense of at least moderate 
improvement. There may be specific patients who have trouble with other medication who may benefit from 
tramadol. She decides not to try tramadol at the moment.
What about the glucosamine she’s noticed in the pharmacy?
You can tell her that while the jury is still out overall, a considerable body of evidence shows that glucosamine 
sulphate 1500 mg/day is more effective for pain control than ibuprofen, and that studies have found glucosamine 
to benefit function. Also, glucosamine may slow disease progression and the need for knee replacement and is 
safe (except in patients with shellfish allergy).
You decide to advise her that taking glucosamine at the recommended dose for at least 2 months is worthwhile. 
She needs to be aware that because glucosamine is sold as a supplement rather than a therapeutic drug, it is not 
subject to the same type of quality control measures as celecoxib. That said, Therapeutic Goods Administration 
data has suggested there is no problem with glucosamine available in Australia.
Table 3. Summary of Cochrane review on glucosamine for osteoarthritis11
•Thereviewincluded2592adultsin20RCTs.Themeanageofparticipantswas
generally 50–70 years. RCT duration was 3 weeks to 3 years 
•Participantsreceivedglucosamineorplacebo/activecontrol.Inallbutonetrial,
glucosamine sulfate (as opposed to glucosamine hydrochloride) was used
•Theresultsweremixed
•GlucosamineoutperformedNSAIDsibuprofenandpiroxicamforpaininthreetrials,
including one top quality trial that followed 319 participants for 20 weeks
•Overall,glucosaminehelpedpainmorethanplacebo.However,concealmentallocation
was adequate in only eight of the 15 relevant trials, and seven out of these 8 trials 
found no difference between glucosamine and placebo
•Itwasunclearwhetherglucosamineimprovedfunctionmorethanplacebo
•Glucosaminewasassafeasplacebo
•AftertheCochranereviewwascompleted,alargeRCTfoundglucosamine
hydrochloride and chondroitin in combination but not individually to be effective for 
moderate to severe knee pain and to have no effect on mild pain. In half of patients 
on this combination, significant improvement occurred at 4 weeks. A further 15% of 
patients had improved significantly at 24 weeks12
•AsubsequentlargeRCTfound4–24weeksofglucosaminesulphate1500mg/daywas
highly effective for relieving pain and improving function in knee OA13
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